Insmed Incorporated INSM
Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing innovative therapies for patients with serious and rare diseases. The company's primary commercial product is ARIKAYCE, an inhaled antibiotic solution used to treat refractory Mycobacterium avium complex (MAC) lung disease, a serious and chronic lung infection. Insmed also has a robust pipeline of investigational therapies, including brensocatib for bronchiectasis and TPIP for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH). The company serves patients, healthcare providers, and healthcare systems primarily in the United States, Japan, and Europe, generating revenue through the sale of its pharmaceutical products and investing heavily in research and development to advance its clinical programs.
LSTM Forecast
Forecast model is not trained yet for this market.
Train and backfill the LSTM forecast to surface a directional view here.